Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Okuno

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncology|August 19, 2024
Long-Term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-Positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 StrategyYuri Oyama, Nobuyoshi Kittaka, Ayako Higuchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 17, 2025
[Current Status and Issue of Emesis and Vomiting Caused by Trastuzumab Deruxtecan]Ai Soma, Fumie Fujisawa, Ayako Higuchi, et al.
Breast Cancer (Tokyo, Japan)|October 2, 2023
Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancerHiroki Kusama, Nobuyoshi Kittaka, Ai Soma, et al.
Cancer Medicine|September 24, 2024
Real-world assessment of comprehensive genome profiling impact on clinical outcomes: A single-institution study in JapanKei Kunimasa, Naotoshi Sugimoto, Tomoyuki Yamasaki, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncology|August 19, 2024
Long-Term Survival Outcomes and Risk Factors for Axillary and Locoregional Recurrence in Japanese Patients with Sentinel Node-Positive Breast Cancer Treated in Accordance with the ACOSOG Z0011 StrategyYuri Oyama, Nobuyoshi Kittaka, Ayako Higuchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 17, 2025
[Current Status and Issue of Emesis and Vomiting Caused by Trastuzumab Deruxtecan]Ai Soma, Fumie Fujisawa, Ayako Higuchi, et al.
Breast Cancer (Tokyo, Japan)|October 2, 2023
Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancerHiroki Kusama, Nobuyoshi Kittaka, Ai Soma, et al.
Cancer Medicine|September 24, 2024
Real-world assessment of comprehensive genome profiling impact on clinical outcomes: A single-institution study in JapanKei Kunimasa, Naotoshi Sugimoto, Tomoyuki Yamasaki, et al.
Pageof 2